Knowing how to give a good talk is a crucial skill to have, but it's mostly not formally taught very well. Here's a 🧵on my strategy for how to prepare for the presentation, actually present it, and then answer the questions.

Out of the Kalluri Lab at MD Anderson Cancer Center & in Cancer Cell Pharmacological inhibition of KRAS G12D w MRTX1133, halts early #PancreaticCancer growth, reprograms the tumor environment & works synergistically w #Immunotherapy #pancsm 💜 OncoAlert 🚨 sciencedirect.com/science/articl…

Thank you Dr. Ryan Corcoran for nice review of our paper! Norbert Kraut Darryl B McConnell @BoettcherJark nature.com/articles/s4301….

Faculty application season is starting up! Here's some thoughts on the process: docs.google.com/document/d/1Ye… Part of Tools for Science: docs.google.com/document/d/1jB… Also, my offer stands for 1-1 mentoring to anyone who wants to chat, just send me an email and we'll find a time!

Happy to share our latest work in collaboration with Haoqiang Ying published in Science Magazine today: Proteostasis network reprogramming is a key convergence point of multiple KRAS inhibitor resistance mechanisms. science.org/doi/10.1126/sc…

Check out the Cancer Discovery papers highlighted in the new AACR Journals collection, Targeting KRAS. bit.ly/44ZBIKQ Norbert Kraut Kevin Haigis Lab Anna Farago, MD, PhD

Next in line is Dongsung Kim (DS(Dongsung) Kim) who works in the Piro Lito lab and will talk about his new inhibitor approach to target KRAS, a protein that was once considered “undruggable”.

Glue-based KRAS inhibitors make their debut cancer trial mark nature.com/articles/d4157… Thoughtful update on the most recent newsflow regarding #KRAS inhibitors #ESMO23 and beyond by Asher Mullard Nature Reviews Drug Discovery

First potent and selective VHL-based pan-#KRAS degraders. Check out the pre-print. Nice work by my colleagues Boehringer Ingelheim and UoD's Alessio Ciulli and Will Farnaby. Congrats to all involved! Targeting cancer with small molecule pan-KRAS degraders biorxiv.org/content/10.110…

We have postdoctoral positions open (see ad below). Projects involve DNA damage signaling mechanisms and development of novel approaches to interrogate kinase/phosphatase action in cells. Come join our lab! Please share / apply.

Another KRAS inhibitor enters the clinic. This is Boehringer Ingelheim orally bioavailable multiKRASi BI-3706674 currently undergoing dose escalation in WT KRAS amplified upper GI cancers. clinicaltrials.gov/study/NCT06056… Cc: David S. Hong MD Dr. Shubham Pant Tim Heffernan Norbert Kraut Daniel Gerlach

Targeting KRAS in cancer | Nature Medicine nature.com/articles/s4159…

Happy Fourth of July, Buckeyes! 🎆

Check out our latest review regarding the biology of RAS GTPase effectors! It was fun to write this with Alessandro Mozzarelli and Simanshu Dhirendra for Molecular Cell. Bottom line: lots of knowledge on these proteins, but many questions that remain to be answered. cell.com/molecular-cell…

A 2022 study suggesting that blocking a molecule could protect against severe #COVID19 illness has led to a $15M NIH grant supporting Ohio State scientists’ work to learn more – with finding a solution to #LongCovid at the center of the new research. bit.ly/3WkdBV9

Interested in the MAPK pathway? Do not miss this virtual conference! EACR Boehringer Ingelheim

Thrilled to share that, together with my colleagues Centre for Targeted Protein Degradation and collaborators Boehringer Ingelheim, we report Science Magazine the breakthrough discovery and characterization of a small-molecule that degrades most oncogenic mutant forms of KRAS. 1/8 science.org/doi/10.1126/sc…

Your weekend treat is waiting at Genes & Development Adrienne Cox & Channing Der Der Lab at UNC have authored a definitive review on the erstwhile “undruggable KRAS”. Starts with the 40 year timeline of discoveries, to the biology and conservation of KRAS signaling, to (of course) current state